Dr. Mark G. Kris

Dr. Mark G. Kris, MD, is a distinguished medical oncologist internationally recognized for his leadership in thoracic oncology and his pioneering work in lung cancer treatment. He serves as the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center (MSKCC), where he has spent decades shaping the field through both clinical practice and groundbreaking research. After receiving his medical degree from Weill Cornell Medical College, Dr. Kris completed his residency in internal medicine at New York-Presbyterian Hospital and a fellowship in oncology at MSKCC. He is board-certified in internal medicine and medical oncology, and he has dedicated his career to advancing care for patients with lung cancer and other thoracic malignancies.

Dr. Kris is widely known for his integral role in developing and evaluating targeted therapies for non-small cell lung cancer (NSCLC), especially those aimed at EGFR and ALK genetic mutations. His research has helped define precision medicine approaches that personalize cancer treatment based on individual tumor biology. In addition to his clinical innovations, Dr. Kris has played a pivotal role in the design and execution of numerous landmark clinical trials that have shaped national treatment standards. He has authored more than 300 peer-reviewed publications, and his work continues to guide oncologists worldwide in the use of molecular diagnostics and tailored therapies.

As a leader in academic medicine, Dr. Kris is deeply involved in mentoring the next generation of oncologists. He serves on editorial boards of leading medical journals and contributes to national cancer policy initiatives through organizations such as the American Society of Clinical Oncology and the National Comprehensive Cancer Network. Renowned for his compassionate care and scientific rigor, Dr. Kris remains at the forefront of thoracic oncology, driving progress in cancer treatment through precision, innovation, and patient-centered care.